LifeMD (NASDAQ:LFMD) Posts Earnings Results, Misses Expectations By $0.01 EPS

LifeMD (NASDAQ:LFMD) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01), FiscalAI reports. LifeMD had a negative return on equity of 150.35% and a net margin of 0.10%.The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million.

Here are the key takeaways from LifeMD’s conference call:

• Q2 profitability missed expectations: Revenue was $47.3 million, but adjusted EBITDA was a $3.5 million loss due to elevated customer acquisition costs and the $39 introductory weight-management offer.
• LifeMD reduced its full-year 2026 outlook to revenue of $205.5 million–$212.5 million and adjusted EBITDA ranging from a $6 million loss to breakeven, while the XYOSTED launch is expected to require $2 million–$3 million of investment this year.
• Underlying business economics improved, with recurring-bill revenue at approximately 84% of total revenue, gross margin expanding to 89%, and sequential reductions of $1.8 million in advertising and $1.5 million in G&A expenses.
• The $39 weight-management offer shifted new patients toward longer-duration plans, with multi-month selections rising from roughly 25% to 85%; management said recent acquisition costs were about 50% below their June peak.
• Management expects adjusted EBITDA profitability in Q3 and Q4 revenue of $60 million–$64 million with adjusted EBITDA of $3 million–$6 million, supported by women’s health growth, pharmacy expansion, insurance initiatives, and new pharmaceutical partnerships.

LifeMD Trading Up 4.7%

LFMD stock traded up $0.16 during trading on Friday, hitting $3.56. The company had a trading volume of 1,264,986 shares, compared to its average volume of 1,099,903. The stock has a market cap of $172.16 million, a PE ratio of -71.19 and a beta of 2.02. LifeMD has a one year low of $2.56 and a one year high of $7.32. The business has a 50-day moving average of $4.40 and a 200-day moving average of $3.97.

Institutional Investors Weigh In On LifeMD

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new position in LifeMD during the fourth quarter worth $36,000. Jain Global LLC purchased a new position in shares of LifeMD during the fourth quarter valued at approximately $45,000. Quarry LP bought a new stake in shares of LifeMD in the 3rd quarter worth $52,000. Tower Research Capital LLC TRC grew its position in LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after acquiring an additional 3,870 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. BTIG Research reduced their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday. KeyCorp set a $5.00 price objective on shares of LifeMD and gave the company an “overweight” rating in a research note on Friday. Finally, HC Wainwright decreased their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.